Healthcare Industry News: Roche
News Release - July 28, 2009
Genentech Announces Appointment of Sandra J. Horning, M.D., To Senior Vice President, Global Head, Clinical Development Hematology/OncologySOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the appointment of Sandra J. Horning, M.D., to senior vice president, global head, Clinical Development Hematology/Oncology.
Beginning in September 2009, Dr. Horning will report to Hal Barron, M.D., executive vice president, Global Development, and chief medical officer in the U.S. In her role, Dr. Horning will be will be a member of the Development Senior Staff and will be responsible for leading the medical and scientific strategies for the global clinical development portfolio in oncology. Dr. Horning will also lead the Disease Biology Leadership Team (DBLT) for Oncology/Hematology. In addition, Dr. Horning will lead and manage Genentech’s team of oncology clinical scientists.
“I’m eager to be joining Genentech,” said Dr. Horning. “They have an unparalleled pipeline of innovative cancer medicines in addition to multiple commercial products that have improved the lives of cancer patients. I look forward to working with an extraordinary team and external collaborators to continue and extend the leading position of Genentech in advancing cancer care.”
“Sandra is driven by her desire to do what is in the best interests of cancer patients,” said Hal Barron. “I look forward to Sandra bringing that drive and her significant expertise to Genentech to benefit the many patients we serve now and in the future.”
Dr. Horning is an internationally recognized oncologist who has made significant contributions to the classification, understanding and treatment of lymphoma. She is a tenured Professor of Medicine (Oncology) at Stanford University School of Medicine and joins Genentech after more than 25 years as a practicing oncologist, investigator and professor at Stanford University. At Stanford, she currently leads the Lymphoma Disease Management group, and she has previously served as chair of Stanford Cancer Center's Scientific Review Committee and was vice-chair of the Department of Medicine at Stanford University Medical School.
In addition to her contributions at Stanford, Dr. Horning has also held many significant leadership roles within the oncology community, most notably as President of ASCO in 2005-2006 and as the Chair of the Lymphoma Committee of the Eastern Cooperative Oncology Group (ECOG) since 1995. At ECOG, Dr. Horning and her colleagues designed numerous clinical trials in lymphoma, specifically two for Rituxan® (Rituximab) in follicular and aggressive non-Hodgkin's lymphoma (E1496/E4494) that led to two important approvals for Genentech and lymphoma patients. Dr. Horning has also served as a panel member of the US Food and Drug Administration’s Oncology Drugs Advisory Committee.
Dr. Horning has authored or co-authored more than 250 peer-reviewed journal articles, book chapters, reviews and editorials, and has served on the editorial boards of several peer-reviewed medical journals, including the Journal of Clinical Oncology, Clinical Cancer Research, Clinical Lymphoma, Leukemia and Lymphoma, the Annals of Internal Medicine, and the American Journal of Medicine. She has been named a “Best Doctor in America” consecutively from 1992-2008.
Dr. Horning earned her medical degree at the University of Iowa, trained in internal medicine at the University of Rochester and completed medical oncology fellowship training at Stanford University.
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a wholly-owned member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.